<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120430009593N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-03-09</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Determination of oxytocin dose based on “rule of threes” algorithm and Williams guideline  in the elective cesarean delivery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation and comparison of administrated oxytocin dose based on “rule of threes” algorithm with Williams guideline  in the elective cesarean delivery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>110</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/37580</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: • Randomization method: Simple randomization 
• Randomization Unit: based on patient 
• Randomization Tool: Random Number Table - block stratified randomization software wnidow version 6.0 Using this software, a random number table is created and the sample list is divided into two groups of 30 each, Blinding description: Participants enter two treatment groups based on a random number table. There is also a ready-made package available to the physician and nurse, including 55 packages of the first and 55 packages of the second drug. The data monitoring committee was also blinded of the grouping.</study_design>
      <phase>3</phase>
      <hc_freetext>Elective cesarean delivery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:The patients in “rule of threes” algorithm group received Bolus oxytocin 3IU/3ml (0.9% saline) . At 3 and 6 min, an “inadequate” uterine tone assessment resulted in repeated bolus administration of oxytocin .  At 9  min, an “inadequate” uterine tone assessment resulted in intramuscular injection of methylergonovine (0.2 mg /ml). At 15 min, inadequate uterine tone assessment resulted in administration of misoprostol 600 µg buccaly. Intervention 2: Intervention group: The William`s group received Bolus oxytocin 3 ml 0.09 % saline and then oxytocin infusion by pump at 15 ml/min  until adequate uterine tonocity  achieved then followed by 1-2 ml/min until patient entrance to recovery. At delivery, 3, 6, 9, 12, and 15 min postpartum, the patients were asked if they had flushing, nausea, chest pain, headache, ECG changes such as ST-T wave changes and other complaints.  To nausea prophylaxis, all patients received ondansetron 4 mg intravenously after the delivery. Total administrated oxcytocin for both groups was finally recorded and then compared.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Some of data can be shared.

When:
Get 6 months after publishing

To whom:
محققین دانشگاهی و کلینیسن ها

Conditions:
For more research

Where to obtain:
Via email: y.ghorbani.m@gmail.com

How to obtain:
After publication

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elham Memari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University Blvd, Velenjak</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 77557840</telephone>
        <email>drmemary@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Yousef Ghorbani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Velenjak, University Blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717443</zip>
        <telephone>+98 21 2243 9781</telephone>
        <email>mpajouhesh@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The women who undergoing to the first to third elective Cesarean delivery with spinal anesthetic technique
American Society of Anesthesiologists (ASA) physical status I–II</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Labor pain
The presence of maternal risk factors for uterine atony
The presence of fetal risk factors for uterine atony
Diabetes melitus
Thrombocytopenia&lt;100000 per microliter
Uterine fibroma</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O82</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for cesarean delivery without indication</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:The patients in “rule of threes” algorithm group received Bolus oxytocin 3IU/3ml (0.9% saline) . At 3 and 6 min, an “inadequate” uterine tone assessment resulted in repeated bolus administration of oxytocin .  At 9  min, an “inadequate” uterine tone assessment resulted in intramuscular injection of methylergonovine (0.2 mg /ml). At 15 min, inadequate uterine tone assessment resulted in administration of misoprostol 600 µg buccaly.</i_keyword>
      <i_keyword>Intervention group: The William`s group received Bolus oxytocin 3 ml 0.09 % saline and then oxytocin infusion by pump at 15 ml/min  until adequate uterine tonocity  achieved then followed by 1-2 ml/min until patient entrance to recovery. At delivery, 3, 6, 9, 12, and 15 min postpartum, the patients were asked if they had flushing, nausea, chest pain, headache, ECG changes such as ST-T wave changes and other complaints.  To nausea prophylaxis, all patients received ondansetron 4 mg intravenously after the delivery. Total administrated oxcytocin for both groups was finally recorded and then compared.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Creating of adequate uterine tonicity. Timepoint: at 3, 6, 9, 12, and 15 min after onset of surgery. Method of measurement: Uterine tonicity was evaluated as atonic, partial tonicity, adequate tonicity, well contracted and very well contracted by obstetrician.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The time of administrated oxytocin to obtain adequate tonicity. Timepoint: At 3, 6, 9, 12, and 15 minute after onset of cesarean. Method of measurement: The mean administrated oxytocin.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-07-10</approval_date>
        <contact_name>The ethical commite of Shahid Beheshti Medical University</contact_name>
        <contact_address>Shahid Beheshti University of Medical Sciences, Shahid Erabi St, Ebne Yaman St, Shahid Chamran Highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
